Media Room

Latest News Releases

Apr 24, 2018

New Oncology Clinical Collaboration between Nektar and Takeda to Evaluate Combination of NKTR-214, a CD122-biased Agonist, and TAK-659, a Dual SYK and FLT-3 Inhibitor, in Liquid and Solid Tumors

Nektar Therapeutics (NASDAQ:NKTR) announced today that it has entered into a new clinical collaboration with Takeda Pharmaceutical Company Limited to evaluate Nektar's investigational medicine,...

Apr 15, 2018

Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2018

Nektar Therapeutics (Nasdaq: NKTR) today announced that it is presenting new preclinical data for its immuno-oncology programs at the American Association for Cancer Research (AACR) Annual Meeting...

Apr 11, 2018

Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors

Nektar Therapeutics (Nasdaq: NKTR) today announced that it has initiated dosing patients in the Phase 1/2 REVEAL clinical study evaluating the efficacy and safety of the combination of...

Multimedia Libraries

Broadcast Video

Image Gallery

Media Contacts

Dan Budwick
Pure Communications, Inc.
[email protected]

Follow @NektarNews

Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide